Q-omics provides the consensus-scored PRICKLE2 profile across patient tissues and cancer cell-line models. PRICKLE2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PRICKLE2 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, PRICKLE2 RNA expression shows 20,554 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, BLCA, and LSCC as cancer lineages where PRICKLE2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRICKLE2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRICKLE2 survival associations across molecular data types. PRICKLE2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRICKLE2 RNA expression–survival associations across cancer types. High PRICKLE2 expression shows unfavorable associations in COAD, but favorable associations in LUAD, UVM, KIRC, KIRP and SKCM. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify LUAD as the clearest survival context for PRICKLE2 RNA expression.
This table summarizes PRICKLE2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PRICKLE2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRICKLE2 shows lower tumor expression in BLCA, KICH, LUAD, LUSC, THCA and COAD. The BLCA box plot shows higher PRICKLE2 RNA expression in normal versus tumor tissue (log2 FC = −2.567, t-test p < 0.001).
This table shows molecular features associated with PRICKLE2 in patient tissues and cancer cell lines. In patient samples, PRICKLE2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRICKLE2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
